November 11, 2022 01:45 PM EST
R&D

IRA im­pact: As­traZeneca and Mer­ck CEOs warn of on­col­o­gy drug de­vel­op­ment shifts

Zachary Brennan

Senior Editor

This lat­est quar­ter­ly earn­ings sea­son for phar­ma has been a time for com­pa­nies to vent about Pres­i­dent Biden’s new drug price ne­go­ti­a­tion law, with some …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times